Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: HMN047
MIFTS: 59

Human Cytomegalovirus Infection

Categories: Blood diseases, Immune diseases, Infectious diseases, Mental diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Human Cytomegalovirus Infection

About this section

MalaCards integrated aliases for Human Cytomegalovirus Infection:

Name: Human Cytomegalovirus Infection 12
Cytomegalovirus Infection 53 29 3 17
Cytomegalovirus Infections 42 70

Classifications:

MalaCards categories:
Global: Infectious diseases
Anatomical: Immune diseases Blood diseases Mental diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:0080827
UMLS 70 C0010823
Sources

Summaries for Human Cytomegalovirus Infection

About this section
NINDS : 53 Cytomegalovirus (CMV) is a virus found throughout the world that infects between 50 to 80 percent of all adults in the United States by the age of 40.  CMV is in the same family of viruses that causes cold sores (herpes simplex virus), infectious mononucleosis (Epstein-Barr virus), and chickenpox/shingles (varicella zoster virus).    Most people who acquire CVM as children or adults display no signs of illness or have mild symptoms such as fever, fatigue, or tender lymph nodes.  People with a compromised immune system may have more severe forms of infection involving the nervous system. A hallmark of CMV infection is that the virus cycles through periods of dormancy and active infection during the life of the individual  Infected persons of any age periodically shed the virus in their body fluids, such as saliva, urine, blood, tears, semen, or breast milk.  CMV is most commonly transmitted when infected body fluids come in contact with the mucous membranes of an uninfected person, but the virus can also pass from mother to fetus during pregnancy.

MalaCards based summary : Human Cytomegalovirus Infection, also known as cytomegalovirus infection, is related to esophagitis and erythema multiforme, and has symptoms including fever and pruritus. An important gene associated with Human Cytomegalovirus Infection is FAS (Fas Cell Surface Death Receptor), and among its related pathways/superpathways are Signaling by GPCR and Innate Immune System. The drugs Azathioprine and Triamcinolone have been mentioned in the context of this disorder. Affiliated tissues include kidney, bone marrow and t cells, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and Decreased shRNA abundance (Z-score < -2)

Disease Ontology : 12 A viral infectious disease that has material basis in Human betaherpesvirus 5.

MedlinePlus : 42 Cytomegalovirus (CMV) is a virus found around the world. It is related to the viruses that cause chickenpox and infectious mononucleosis (mono). Between 50 percent and 80 percent of adults in the United States have had a CMV infection by age 40. Once CMV is in a person's body, it stays there for life. CMV is spread through close contact with body fluids. Most people with CMV don't get sick and don't know that they've been infected. But infection with the virus can be serious in babies and people with weak immune systems. If a woman gets CMV when she is pregnant, she can pass it on to her baby. Usually the babies do not have health problems. But some babies can develop lifelong disabilities. A blood test can tell whether a person has ever been infected with CMV. Most people with CMV don't need treatment. If you have a weakened immune system, your doctor may prescribe antiviral medicine. Good hygiene, including proper hand washing, may help prevent infections. Centers for Disease Control and Prevention

CDC : 3 Cytomegalovirus (pronounced sy-toe-MEG-a-low-vy-rus), or CMV, is a common virus that infects people of all ages. Over half of adults by age 40 have been infected with CMV. Most people infected with CMV show no signs or symptoms. When a baby is born with cytomegalovirus (CMV) infection, it is called congenital CMV. About one out of every 200 babies is born with congenital CMV infection. About one in five babies with congenital CMV infection will have long-term health problems.

Sources

Related Diseases for Human Cytomegalovirus Infection

About this section

Diseases related to Human Cytomegalovirus Infection via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1109)
# Related Disease Score Top Affiliating Genes
1 esophagitis 30.8 IL6 IL1B CXCL8
2 erythema multiforme 30.8 IL6 CXCL8 CCL5
3 gastritis 30.7 IL6 IL1B CXCL8 CCL5
4 encephalitis 30.7 IRF3 IL6 IL1B CCL5
5 bronchiolitis 30.6 IL6 IL1B CXCL8 CCL5
6 perinatal necrotizing enterocolitis 30.6 IL6 IL1B CXCL8
7 lymphocytic choriomeningitis 30.6 IRF3 IL6 CXCL8
8 exanthem 30.6 MTOR IL6 IL1B EGFR CXCL8
9 pharyngitis 30.5 IL6 IL1B CXCL8
10 liver disease 30.5 IL6 IL1B FAS CXCL8 CASP3
11 syphilis 30.5 IL6 HLA-C FAS
12 rubella 30.5 IL6 IL1B HLA-C HLA-A
13 thrombocytopenia 30.4 PDGFRA IL6 IL1B HLA-A FAS CXCL8
14 diarrhea 30.4 IL6 IL1B EGFR CXCL8
15 pericarditis 30.4 IL6 IL1B CXCL8
16 malignant astrocytoma 30.4 PDGFRA EGFR CDKN2A CASP3
17 neuritis 30.4 IL6 IL1B CXCL8 CCL5
18 viral pneumonia 30.3 IL6 CXCL8 CCL5
19 high grade glioma 30.3 PDGFRA MTOR EGFR CDKN2A CASP3
20 sarcoma 30.3 PDGFRA MTOR IL6 CXCL8 CASP3
21 gastric ulcer 30.3 IL6 IL1B CXCL8
22 bacterial sepsis 30.3 IL6 IL1B CXCL8
23 chlamydia pneumonia 30.3 IL6 IL1B CXCL8
24 encephalomalacia 30.3 IL6 IL1B CXCL8 CASP3
25 chlamydia 30.3 IL6 IL1B CXCL8
26 tonsillitis 30.3 IL6 IL1B CXCL8
27 duodenal ulcer 30.2 IL6 IL1B CXCL8
28 acute transverse myelitis 30.2 IL6 CXCL8
29 adult-onset still's disease 30.2 IL6 IL1B CXCL8
30 t-cell lymphoblastic leukemia/lymphoma 30.2 IKBKB FAS CREB1 CHUK CASP3
31 stevens-johnson syndrome/toxic epidermal necrolysis 30.2 HLA-C HLA-A
32 aspergillosis 30.2 IL6 IL1B CXCL8 CCL5
33 lung disease 30.1 IL6 IL1B EGFR CXCL8 CCL5
34 allergic disease 30.1 IL6 IL1B CXCL8 CCL5
35 radiculopathy 30.1 IL6 CXCL8 CCL5
36 oral cancer 30.1 EGFR CDKN2A CASP3
37 erythema nodosum 30.1 IL6 IL1B CXCL8
38 appendicitis 30.1 IL6 IL1B CXCL8
39 bacterial pneumonia 30.1 IL6 IL1B CXCL8
40 leukemia, acute monocytic 30.1 IL6 IL1B CXCL8
41 bacterial vaginosis 30.0 IL6 IL1B CXCL8
42 optic neuritis 30.0 IL6 IL1B HLA-A CXCL8
43 toxic shock syndrome 30.0 IL6 IL1B EGFR CXCL8
44 lymphadenitis 30.0 IL1B FAS CXCL8 CASP3
45 aplastic anemia 30.0 MTOR IL6 IL1B HLA-A FAS CXCL8
46 temporal arteritis 30.0 IL6 IL1B CCL5
47 mucositis 30.0 MTOR IL1B CASP3
48 listeriosis 30.0 IRF3 IL6 IL1B
49 chorioamnionitis 30.0 IL6 IL1B CXCL8
50 lymphoma, non-hodgkin, familial 30.0 IL6 HLA-A FAS CHUK CASP3

Comorbidity relations with Human Cytomegalovirus Infection via Phenotypic Disease Network (PDN):


Acute Cystitis Deficiency Anemia
Heart Disease

Graphical network of the top 20 diseases related to Human Cytomegalovirus Infection:



Diseases related to Human Cytomegalovirus Infection
Sources

Symptoms & Phenotypes for Human Cytomegalovirus Infection

About this section

UMLS symptoms related to Human Cytomegalovirus Infection:


fever; pruritus

GenomeRNAi Phenotypes related to Human Cytomegalovirus Infection according to GeneCards Suite gene sharing:

26 (show all 30)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-103 10.86 HLA-A HLA-C HLA-G
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-110 10.86 HLA-A HLA-C HLA-G
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-118 10.86 EGFR
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-14 10.86 HLA-C
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-156 10.86 HLA-A HLA-C HLA-G
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-178 10.86 HLA-A HLA-C HLA-G
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-19 10.86 HLA-A HLA-C HLA-G
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-190 10.86 EGFR
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-202 10.86 HLA-C
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-31 10.86 HLA-A HLA-C HLA-G HLA-E
11 Decreased shRNA abundance (Z-score < -2) GR00366-A-58 10.86 EGFR
12 Decreased shRNA abundance (Z-score < -2) GR00366-A-61 10.86 HLA-E
13 Decreased shRNA abundance (Z-score < -2) GR00366-A-7 10.86 HLA-A HLA-C HLA-G
14 Decreased shRNA abundance (Z-score < -2) GR00366-A-91 10.86 HLA-C
15 Decreased shRNA abundance (Z-score < -2) GR00366-A-95 10.86 HLA-C
16 Decreased viability GR00055-A-1 10.5 EGFR MTOR
17 Decreased viability GR00055-A-2 10.5 EGFR MTOR
18 Decreased viability GR00173-A 10.5 PDGFRA
19 Decreased viability GR00221-A-1 10.5 CDKN2A CHUK EGFR MTOR PDGFRA
20 Decreased viability GR00221-A-3 10.5 CDKN2A PDGFRA
21 Decreased viability GR00221-A-4 10.5 CDKN2A CHUK EGFR MTOR PDGFRA
22 Decreased viability GR00249-S 10.5 PDGFRA
23 Decreased viability GR00342-S-1 10.5 CHUK MTOR
24 Decreased viability GR00342-S-2 10.5 MTOR
25 Decreased viability GR00402-S-2 10.5 PDGFRA
26 Decreased interferon-beta reporter expression GR00307-A 9.62 CXCL8 HLA-E IKBKB IRF3
27 Decreased viability with paclitaxel GR00179-A-1 9.35 EGFR MTOR
28 Decreased viability with paclitaxel GR00179-A-2 9.35 MTOR
29 Decreased viability with paclitaxel GR00179-A-3 9.35 EGFR MTOR
30 Increased viability with paclitaxel GR00179-A-1 8.32 CASP3

MGI Mouse Phenotypes related to Human Cytomegalovirus Infection:

46 (show all 14)
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.41 CASP3 CCL5 CCR1 CDKN2A CHUK EGFR
2 homeostasis/metabolism MP:0005376 10.36 CASP3 CCR1 CDKN2A CHUK CREB1 EGFR
3 immune system MP:0005387 10.36 CASP3 CCL5 CCR1 CDKN2A CHUK EGFR
4 cardiovascular system MP:0005385 10.35 CASP3 CCR1 CDKN2A CHUK CREB1 EGFR
5 cellular MP:0005384 10.3 CASP3 CCR1 CDKN2A CHUK CREB1 EGFR
6 endocrine/exocrine gland MP:0005379 10.24 CASP3 CDKN2A CHUK CREB1 EGFR FAS
7 digestive/alimentary MP:0005381 10.16 CASP3 CCR1 CDKN2A CHUK EGFR FAS
8 nervous system MP:0003631 10.07 CASP3 CDKN2A CHUK CREB1 EGFR ELK1
9 integument MP:0010771 10.06 CASP3 CDKN2A CHUK EGFR FAS IKBKB
10 muscle MP:0005369 10.02 CASP3 CDKN2A CREB1 EGFR FAS IKBKB
11 neoplasm MP:0002006 9.87 CDKN2A CHUK EGFR FAS IL1B IL6
12 renal/urinary system MP:0005367 9.81 CASP3 CCR1 CHUK EGFR FAS IL6
13 respiratory system MP:0005388 9.7 CASP3 CCR1 CDKN2A CHUK CREB1 EGFR
14 skeleton MP:0005390 9.32 CASP3 CDKN2A CHUK CREB1 EGFR FAS
Sources

Drugs & Therapeutics for Human Cytomegalovirus Infection

About this section

Drugs for Human Cytomegalovirus Infection (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 155)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Azathioprine Approved Phase 4 446-86-6 2265
2
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
3
Tacrolimus Approved, Investigational Phase 4 104987-11-3 6473866 445643 439492
4
Mycophenolic acid Approved Phase 4 24280-93-1 446541
5
Clotrimazole Approved, Vet_approved Phase 4 23593-75-1 2812
6
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
7
tannic acid Approved Phase 4 1401-55-4
8
Sirolimus Approved, Investigational Phase 4 53123-88-9 6436030 5284616
9
Basiliximab Approved, Investigational Phase 4 152923-56-3, 179045-86-4
10
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
11
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
12
Everolimus Approved Phase 4 159351-69-6 6442177 70789204
13
Magnesium Sulfate Approved, Investigational, Vet_approved Phase 4 7487-88-9 24083
14
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
15
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
16
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
17
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
18
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
19
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
20
Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
21
Formaldehyde Approved, Vet_approved Phase 4 50-00-0 712
22
Foscarnet Approved Phase 4 63585-09-1, 4428-95-9 3415
23
Ganciclovir Approved, Investigational Phase 4 82410-32-0 3454
24
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
25
Phosphonoacetic Acid Experimental Phase 4 4408-78-0 546
26 Triamcinolone diacetate Phase 4
27 Triamcinolone hexacetonide Phase 4
28 triamcinolone acetonide Phase 4
29 Liver Extracts Phase 4
30 Antibiotics, Antitubercular Phase 4
31 Immunosuppressive Agents Phase 4
32 Immunologic Factors Phase 4
33 Anti-Bacterial Agents Phase 4
34 Calcineurin Inhibitors Phase 4
35 Antitubercular Agents Phase 4
36 Hormone Antagonists Phase 4
37 Protective Agents Phase 4
38 Analgesics Phase 4
39 Anti-Inflammatory Agents Phase 4
40 Antifungal Agents Phase 4
41 Hormones Phase 4
42 glucocorticoids Phase 4
43 Antineoplastic Agents, Hormonal Phase 4
44 Anti-Arrhythmia Agents Phase 4
45 Anesthetics Phase 4
46 Tocolytic Agents Phase 4
47 Anticonvulsants Phase 4
48 calcium channel blockers Phase 4
49 Calcium, Dietary Phase 4
50 Gastrointestinal Agents Phase 4

Interventional clinical trials:

(show top 50) (show all 256)
# Name Status NCT ID Phase Drugs
1 Conversion to Sirolimus: Effects in Cytomegalovirus Infection Recurrence in Kidney Transplant Recipients (StopCMV: S=Sirolimus CMV= Cytomegalovirus) Unknown status NCT02671318 Phase 4 Drug conversion to sirolimus;Maintenance of the current regimen
2 An Exploratory Evaluation of Early Use of Everolimus (EVE) on Tacrolimus (TAC)-Based Immunosuppressive Regiment vs. Mycophenolate Sodium (MPS) on Cytomegalovirus (CMV) Infection in Renal Transplant Recipients. Unknown status NCT01927588 Phase 4 Everolimus+Tacrolimus+Prednisone;Mycophenolate+Tacrolimus+Prednisone
3 Prophylaxis Versus Preemptive Therapy for the Prevention of CMV in High-Risk R-D+ Liver Transplant Recipients Completed NCT01552369 Phase 4 Valganciclovir
4 Tacrolimus In Combination, Tacrolimus Alone Compared (TICTAC Trial): A Prospective Randomized Trial Of Minimized Immunosuppression In Adult Heart Transplant Recipients Completed NCT00299221 Phase 4 Tacrolimus;combination therapy
5 In Utero Treatment of Cytomegalovirus congénitale Infection With Valacyclovir : Prospective Multicenter Nonrandomized Trial Completed NCT01651585 Phase 4 Valacyclovir arrow
6 The Influence of Chronic Cytomegalovirus Infection on Influenza Vaccine Responses Completed NCT02134184 Phase 4
7 Determining a Viral Load Threshold for Pre-emptive Therapy for Cytomegalovirus Infection in Transplant Patients Using Real Time Polymerase Chain Reaction (PCR) Monitoring Completed NCT00947141 Phase 4 ganciclovir (start when CMV PCR >200copies / ml x2);Stop treatment when 2 levels CMV PCR <3,000 copies / ml
8 Phase IV.II Pilot Study of Treatment of Cytomegalovirus Infection With a Brief Induction With Ganciclovir i.v. Followed by Valganciclovir Oral in Solid Organ Transplant Patients. Completed NCT00730769 Phase 4 Single arm (ganciclovir and valganciclovir)
9 Safety and Efficacy of Intravenous Magnesium Sulfate in Modulating Changes in Symptoms and Divalent Cation Levels Associated With Foscavir Therapy: A Phase IV Randomized, Double-Blind, Placebo-Controlled, Cross-Over, Pilot Study Completed NCT00002146 Phase 4 Magnesium sulfate;Foscarnet sodium
10 A Randomized, Open-label Study of the Effect of Oral Valcyte Versus Intravenous Ganciclovir on CMV Viremia in Solid Organ Transplant Patients Completed NCT00431353 Phase 4 Ganciclovir;valganciclovir [Valcyte]
11 Tolerability of up to 200 Days of Valganciclovir Oral Solution or Tablets in Pediatric Kidney Transplant Recipients Completed NCT01376804 Phase 4 valganciclovir [Valcyte]
12 A Multicenter Prospective Cohort Study to Investigate if Ganciclovir Significantly Affects Spermatogenesis in Adult Male Renal Transplant Recipients Receiving up to 200 Days Valganciclovir Vs. Concurrent Untreated Matched Controls Completed NCT01663740 Phase 4 Valganciclovir
13 Efficacy and Safety of Induction Strategies Combined With Low Tacrolimus Exposure in Kidney Transplant Recipients Receiving Everolimus or Sodium Mycophenolate Completed NCT01354301 Phase 4 Thymoglobulin;Everolimus;Basiliximabe;mycophenolate sodium;Tacrolimus;Tacrolimus;Tacrolimus
14 A Multicenter, Two Arms, Randomized, Open Label Clinical Phase IV Study Investigating the Proportion of CMV Seropositive Kidney Transplant Recipients Who Will Develop a CMV Infection Within the First 6 Months Post-transplantation When Treated With an Immunosuppressive Regimen Including Everolimus (Certican®) and Reduced Dose of Cyclosporine A (Neoral®) Versus an Immunosuppressive Regimen With Mycophenolic Acid (Myfortic®) and Standard Dose of Cyclosporine A (Neoral®). Completed NCT02328963 Phase 4 Everolimus;mycophenolic acid
15 Cytogam Administration in Abdominal Organ Transplant Recipients at High Risk for CMV Infection Completed NCT01509404 Phase 4 Valganciclovir;Valganciclovir
16 Influence of Persistent CMV-infection on Immune Senescence Evaluated With a Prospective Vaccination Trial Against Tick-borne Encephalitis Virus in Healthy Elderly Individuals (CYTEL-Study) Completed NCT00461695 Phase 4
17 Open, Randomised Study Comparing Preemptive Therapy With Intravenous Ganciclovir With and Without Additional Oral Ganciclovir for CMV Prophylaxis in Immunosuppressed Renal Transplant Patients Receiving Monitoring of CMV Viral Load Completed NCT00373165 Phase 4 Ganciclovir
18 Valganciclovir to Reduce T Cell Activation in HIV Infection Completed NCT00264290 Phase 4 Valganciclovir;Placebo
19 Sirolimus Associated With Tacrolimus at Low Doses in Elderly Kidney Transplant Patients: A Prospective Randomized Controlled Trial Completed NCT02683291 Phase 4 sirolimus;tacrolimus;mycophenolate;Prednisone;Basiliximab;Thymoglobulin
20 A Prospective Randomized Study for Predicting Human Cytomegalovirus (hCMV) Infection According to Baseline hCMV-specific T-cell Response in Kidney Transplant Patients (RESPECT) Completed NCT02550639 Phase 4
21 Everolimus in Association With Very Low-dose Tacrolimus Versus Enteric-coated Mycophenolate Sodium With Low-dose Tacrolimus in de Novo Renal Transplant Recipients - A Prospective Single Center Study Completed NCT02084446 Phase 4 Everolimus;Very Low Tacrolimus;Low Tacrolimus;Steroids;Thymoglobulin;Sodium Mycophenolate
22 Cytomegalovirus Specific Cytotoxic T Lymphocyte for the Treatment of Cytomegalovirus Infection After Allogeneic Hematopoietic Stem Cell Transplantation Recruiting NCT03004261 Phase 4 Foscarnet;Ganciclovir
23 Phase IV Clinical Trial, Open, Randomized, Controlled and Multicentric, With Two Parallel Groups, to Assess the Efficacy of a Preventive Strategy Against Cytomegalovirus Infection in Heart Transplant Patients, Based on the Specific Basal T Cell Response Against Cytomegalovirus: ELISPOT-TC Recruiting NCT04278547 Phase 4
24 Intra-cameral Penetration and Efficacy of Ganciclovir Following Topical Administration of 2% Ganciclovir Eye Drop for CMV Anterior Uveitis / Endotheliitis Recruiting NCT02943057 Phase 4 2% guttae ganciclovir
25 In UTERO Treatment of Cytomegalovirus Congenital Infection With Valacyclovir: Prospective Multicenter Randomized Trial Versus Placebo Terminated NCT01037712 Phase 4 Valacyclovir (ZELITREX);Placebo
26 Ganciclovir Pharmacokinetics in Patients Undergoing Continuous Renal Replacement Therapy Terminated NCT00264368 Phase 4 intravenous (IV) ganciclovir
27 The Impact of Co-infections on Inflammation in Patients Commencing Second-line Antiretroviral Therapy. A Sub-study of D²EFT (Dolutegravir and Darunavir Evaluation in Adults Failing Therapy) Withdrawn NCT04183738 Phase 4 NRTIs;Darunavir;Ritonavir;Dolutegravir
28 The Leiden CONCERT Study 2.0 Congenital Cytomegalovirus: Efficacy of Antiviral Treatment in a Non-Randomized Trial With Historical Control Group Unknown status NCT02005822 Phase 3 Valganciclovir
29 Efficacy and Safety of Anti-cytomegalovirus Prophylaxis Versus Pre-emptive Approaches With Valganciclovir in Heart Transplant Recipients Treated With Everolimus or Mycophenolate. A Randomized Open-label Study for Prevention of Cardiaca Allograft Vasculopathy Unknown status NCT00966836 Phase 3 Pre-emptive strategy with valganciclovir plus everolimus;Prophylaxis with valganciclovir plus mycophenolate;Prophylaxis with valganciclovir plus everolimus;Pre-emptive mycophenolate
30 Phase III Randomized, Controlled Study of Ganciclovir for Symptomatic Congenital Cytomegalovirus Infection Completed NCT00004278 Phase 3 ganciclovir
31 Participation of Cytomegalovirus Infection or an Autoimmune Process in T Lymphocyte Activation of HIV-1 Infected Patients With Undetectable Viral Load on Antiretroviral Therapy. Completed NCT04067869 Phase 3
32 A Phase III Multicenter Study Of Valganciclovir For The Prevention Of Late Cytomegalovirus Infection After Allogeneic Hematopoietic Stem Cell Transplantation Completed NCT00016068 Phase 3 ganciclovir;valganciclovir
33 A Phase III, Randomized, Placebo-Controlled Blinded Investigation of Six Weeks vs. Six Months of Oral Valganciclovir Therapy in Infants With Symptomatic Congenital Cytomegalovirus Infection (CASG 112) Completed NCT00466817 Phase 3 Valganciclovir
34 A Phase III Multicenter Study of Valganciclovir for the Prevention of Late Cytomegalovirus Infection After Allogenic Hematopoietic Stem Cell Transplantation. Completed NCT00275665 Phase 3 Valganciclovir
35 A Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Prophylactic Use of Maribavir for the Prevention of Cytomegalovirus Disease in Recipients of Allogeneic Stem Cell Transplants. Completed NCT00411645 Phase 3 maribavir
36 A Randomized Trial Comparing Valcyte CMV Prophylaxis Versus Pre-emptive Therapy After Renal Transplantation Using Proteomics for Monitoring of Graft Alteration Completed NCT00372229 Phase 3 Valganciclovir CMV Prophylaxis;Valganciclovir (Pre-emptive CMV Therapy);Ganciclovir
37 A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of the Efficacy and Safety of up to 100 Days of Valganciclovir Versus up to 200 Days of Valganciclovir for Prevention of Cytomegalovirus (CMV) Disease in High-Risk Kidney Allograft Recipients Completed NCT00294515 Phase 3 Valganciclovir;Valganciclovir
38 Phase III Study Evaluating the Safety and Efficacy of Artesunate in Preemptive Treatment of Human Cytomegalovirus Disease in Stem Cell Transplant Recipients Completed NCT00284687 Phase 3 Artesunate
39 A Randomized, Double-Blind Trial of Valacyclovir Hydrochloride (BW 256U87) Prophylaxis for Opportunistic Cytomegalovirus End-Organ Disease in Patients With Advanced HIV Infection (< 100 CD4+ Lymphocytes) Completed NCT00001038 Phase 3 Valacyclovir hydrochloride;Acyclovir
40 A Phase III Study to Evaluate the Safety and Efficacy of Ganciclovir (Dihydroxypropoxymethyl Guanine [DHPG]) Treatment of Symptomatic Central Nervous System (CNS) Congenital Cytomegalovirus (CMV) Infections. Completed NCT00001100 Phase 3 ganciclovir
41 A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Adefovir Dipivoxil (Bis-POM PMEA) in Prolonging Survival of HIV-Infected Individuals With a CD4+ Cell Count of <= 100/mm3 or With a CD4+ Cell Count Both > 100 and <= 200/mm3 and a Nadir CD4+ Cell Count of <= 50/mm3 Completed NCT00001082 Phase 3 Levocarnitine;Adefovir dipivoxil;Adefovir dipivoxil placebo
42 Safety and Pharmacokinetics of Valganciclovir Syrup Formulation in Pediatric Solid Organ Transplant Recipients Completed NCT00090766 Phase 2, Phase 3 valganciclovir [Valcyte]
43 A Randomized, Double-blind Study To Assess The Efficacy And Safety Of Prophylactic Use Of Maribavir Versus Oral Ganciclovir For The Prevention Of Cytomegalovirus Disease In Recipients Of Orthotopic Liver Transplants Completed NCT00497796 Phase 3 maribavir;ganciclovir
44 A Phase III, Randomized, Double-Blind Comparison of Oral Valganciclovir and Placebo for Prevention of CMV After Lung Transplantation Completed NCT00227370 Phase 3 valganciclovir
45 A Phase III, Prospective, Randomized, Double-Blind Trial of Valganciclovir Pre-Emptive Therapy for Cytomegalovirus (CMV) Viremia as Detected by Plasma CMV DNA PCR Assay Completed NCT00006145 Phase 3 Valganciclovir
46 Valacyclovir to Prevent Vertical Transmission of Cytomegalovirus After Maternal Primary Infection During Pregnancy Completed NCT02351102 Phase 2, Phase 3 Valacyclovir;Placebo
47 A Phase III Randomised Study to Investigate the Use of Adoptive Cellular Therapy (ACT) in Combination With Conventional Antiviral Drug Therapy for the Treatment of CMV Reactivation Episodes in Patients Following Allogeneic Haematopoietic Stem Cell Transplant Completed NCT01077908 Phase 3 Best available antiviral drug therapy
48 Prevention of Human Cytomegalovirus (HCMV) Mother-to-fetus Transmission by Administration of Virus-specific Hyperimmune Globulin to Pregnant Women With Primary HCMV Infection Completed NCT00881517 Phase 2, Phase 3 HCMV-specific hyperimmune globulin (Cytotect®);Isotonic solution of sodium chloride (placebo)
49 Transfusion-Transmitted Cytomegalovirus Prevention in Neonates Completed NCT00000584 Phase 3 immunoglobulins
50 A Phase III Randomized, Placebo-controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-8228 (Letermovir) for the Prevention of Clinically Significant Human Cytomegalovirus (CMV) Infection in Adult, CMV-Seropositive Allogeneic Hematopoietic Stem Cell Transplant Recipients Completed NCT02137772 Phase 3 Letermovir;Placebo

Search NIH Clinical Center for Human Cytomegalovirus Infection

Inferred drug relations via UMLS 70 / NDF-RT 51 :


Cidofovir
Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor [EPC]
Cytomegalovirus Pyrophosphate Analog DNA Polymerase Inhibitor [EPC]
Foscarnet
Foscarnet Sodium Hexahydrate
Ganciclovir
Ganciclovir Sodium
Immunoglobulins, Intravenous
valganciclovir
Valganciclovir hydrochloride
Sources

Genetic Tests for Human Cytomegalovirus Infection

About this section

Genetic tests related to Human Cytomegalovirus Infection:

# Genetic test Affiliating Genes
1 Cytomegalovirus Infection 29
Sources

Anatomical Context for Human Cytomegalovirus Infection

About this section

MalaCards organs/tissues related to Human Cytomegalovirus Infection:

40
Kidney, Bone Marrow, T Cells, Brain, Endothelial, Liver, Pancreas
Sources

Publications for Human Cytomegalovirus Infection

About this section

Articles related to Human Cytomegalovirus Infection:

(show top 50) (show all 8622)
# Title Authors PMID Year
1
Diagnosis of GATA2 Deficiency in a Young Woman with Hemophagocytic Lymphohistiocytosis Triggered by Acute Systemic Cytomegalovirus Infection. 42 61
33684095 2021
2
Virus-specific memory T cell responses unmasked by immune checkpoint blockade cause hepatitis. 42
33664251 2021
3
Human Cytomegalovirus and Autoimmune Diseases: Where Are We? 42
33567734 2021
4
Patients with Helicobacter pylori-positive gastric cancer with human cytomegalovirus infection have a low tendency of advanced lymphatic metastasis in a Chinese population. 61
33777225 2021
5
Opportunistic Infections After Induction With Alemtuzumab or Basiliximab: A 3-Year Kidney Transplantation Experience. 61
32921434 2021
6
Long-Term Outcome of ABO-Incompatible Kidney Transplantation in Patients Treated With Low-Dose Rituximab Regimen. 61
33272650 2021
7
Virus-specific NK cell memory. 61
33755720 2021
8
Influence of Donor Transmitted and Rapidly Progressive Coronary Vascular Disease on Long-Term Outcomes After Heart Transplantation: A Contemporary Intravascular Ultrasound Analysis. 61
33358960 2021
9
Outcome of fetuses with congenital cytomegalovirus infection and normal ultrasound at diagnosis: systematic review and meta-analysis. 61
33030767 2021
10
Degos-like lesions as a cutaneous manifestation of cytomegalovirus infection: A rare and serious complication in a patient with drug-induced hypersensitivity syndrome. 61
33305840 2021
11
Replicable association between human cytomegalovirus infection and reduced white matter fractional anisotropy in major depressive disorder. 61
33500556 2021
12
Human cytomegalovirus infection: A considerable issue following allogeneic hematopoietic stem cell transplantation. 61
33692850 2021
13
First-trimester diagnosis of congenital cytomegalovirus infection after maternal primary infection in early pregnancy: feasibility study of viral genome amplification by PCR on chorionic villi obtained by CVS. 61
33533526 2021
14
Cytomegalovirus tubulo-glomerulitis and intratubular granuloma: Key histopathological findings in allograft cytomegalovirus infection. 61
33150713 2021
15
Outcome of pregnancies with recent primary cytomegalovirus infection in first trimester treated with hyperimmunoglobulin: observational study. 61
33491819 2021
16
Population pharmacokinetics of letermovir following oral and intravenous administration in healthy participants and allogeneic hematopoietic cell transplantation recipients. 61
33440077 2021
17
Imbalance of acquired immunity factors in newborns with cytomegaloviral infection depending on the severity of the disease. 61
33793116 2021
18
Is simultaneous partial splenectomy during pediatric liver transplantation safe and effective for severe hypersplenism? A prospective cohort study. 61
33746054 2021
19
Post-Transplant Cyclophosphamide (PTCy) is Associated with Increased Cytomegalovirus Infection: A CIBMTR Analysis. 61
33657221 2021
20
Pregnant women's knowledge and behaviour to prevent cytomegalovirus infection: an observational study. 61
33095754 2021
21
New-Onset Diabetes after Kidney Transplantation. 61
33800138 2021
22
A new MRI severity score to predict long-term adverse neurologic outcomes in children with congenital Cytomegalovirus infection. 61
31096816 2021
23
A prospective study evaluating congenital CMV infection in Mayotte and La Reunion Islands (France). 61
33770656 2021
24
Human immunodeficiency virus infection with multiple opportunistic infections: lessons learnt from a non-adherent patient. 61
33732476 2021
25
Menetrier disease and Cytomegalovirus infection in paediatric age: report of three cases and a review of the literature. 61
32803424 2021
26
Acute lymphoblastic leukemia complicating with adrenal insufficiency due cytomegalovirus infection. 61
33716022 2021
27
Cytomegalovirus infection in pregnancy - An update. 61
33454510 2021
28
Late-onset allograft rejection, cytomegalovirus infection, and renal allograft loss: Is anti-CMV prophylaxis required following late-onset allograft rejection? 61
33713374 2021
29
Latent cytomegalovirus infection and previous capsular polysaccharide vaccination predict poor vaccine responses in older adults, independent of chronic kidney disease. 61
33728434 2021
30
Sensitivity of Dried Blood Spot Testing for Detection of Congenital Cytomegalovirus Infection. 61
33523119 2021
31
Brain MRI findings in newborns with congenital cytomegalovirus infection: results from a large cohort study. 61
33787973 2021
32
Hypoxia-Inducible Factor 1α (HIF1α) Suppresses Virus Replication in Human Cytomegalovirus Infection by Limiting Kynurenine Synthesis. 61
33758082 2021
33
Fluorometric Viral miRNA Nanosensor for Diagnosis of Productive (Lytic) Human Cytomegalovirus Infection in Living Cells. 61
33529521 2021
34
Potential Impact of Human Cytomegalovirus Infection on Immunity to Ovarian Tumours and Cancer Progression. 61
33808294 2021
35
Cell type-specific biogenesis of novel vesicles containing viral products in human cytomegalovirus infection. 61
33762413 2021
36
Epigenetic reprogramming of host and viral genes by Human Cytomegalovirus infection in Kasumi-3 myeloid progenitor cells at early times post-infection. 61
33731453 2021
37
Amniotic fluid peptides predict postnatal kidney survival in developmental kidney disease. 61
32750455 2021
38
Portal and mesenteric thrombosis secondary to acute cytomegalovirus infection in an immunocompetent patient. 61
33008668 2021
39
Outcomes of Infection and Risk of Mortality in Liver Transplant Patients with Simultaneous Splenectomy. 61
33604862 2021
40
Absorption, Metabolism, Distribution, and Excretion of Letermovir. 61
33622223 2021
41
Cytomegalovirus chemokine receptor M33 knockout reduces chronic allograft rejection in a murine aortic transplant model. 61
33301898 2021
42
Effects of Chronic Viral Infection on Lymphocyte Populations in Middle‑aged Baboons (Papio anubis). 61
33579397 2021
43
Assessment of Pharmacokinetic Interaction Between Letermovir and Fluconazole in Healthy Participants. 61
32700459 2021
44
Range and Consistency of Infection Outcomes Reported in Trials Conducted in Kidney Transplant Recipients: a Systematic Review. 61
33653998 2021
45
Bimonthly viral monitoring for late-onset cytomegalovirus infection in kidney transplant recipients. 61
33605490 2021
46
The NFKB1 Promoter Polymorphism (-94ins/delATTG) Is Associated with Susceptibility to Cytomegalovirus Infection after Kidney Transplantation and Should Have Implications on CMV Prophylaxis Regimens. 61
33673169 2021
47
Letermovir for the compassionate therapeutic use of cytomegalovirus infection. 61
32914220 2021
48
Abdominal aortic aneurysm and virus infection: a potential causative role for cytomegalovirus infection? 61
33629381 2021
49
Wavy Floating Greater Omentum Findings Are Useful for Differentiating the Etiology of Fetal Ascites. 61
33671226 2021
50
Cytomegalovirus infection as an underestimated trigger for checkpoint inhibitor-related pneumonitis in lung cancer: a retrospective study. 61
32613413 2021
Sources

Variations for Human Cytomegalovirus Infection

About this section
Sources

Expression for Human Cytomegalovirus Infection

About this section
Search GEO for disease gene expression data for Human Cytomegalovirus Infection.
Sources

Pathways for Human Cytomegalovirus Infection

About this section

Pathways related to Human Cytomegalovirus Infection according to GeneCards Suite gene sharing:

(show top 50) (show all 143)
# Super pathways Score Top Affiliating Genes
1
Signaling by GPCR 65
Show member pathways
 14.3 PDGFRA MTOR IL6 IKBKB FAS ELK1
2
Innate Immune System 65
Show member pathways
 14.06 PDGFRA MTOR IRF3 IL6 IL1B IKBKB
3
Apoptotic Pathways in Synovial Fibroblasts 63
Show member pathways
 13.97 PDGFRA IL6 IL1B IKBKB FAS ELK1
4
ERK Signaling 63
Show member pathways
 13.92 PDGFRA MTOR IL6 IL1B FAS ELK1
5
PEDF Induced Signaling 63
Show member pathways
 13.78 PDGFRA MTOR IL6 IL1B IKBKB FAS
6
TGF-Beta Pathway 63
Show member pathways
 13.67 PDGFRA MTOR IL6 IL1B IKBKB ELK1
7
Class I MHC mediated antigen processing and presentation 65
Show member pathways
 13.59 PDGFRA MTOR IKBKB HLA-G HLA-E HLA-C
8
Pathways of neurodegeneration - multiple diseases 36
Show member pathways
 13.58 MTOR IL6 IL1B IKBKB FAS CREB1
9
Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins. 65
Show member pathways
 13.52 MTOR IL6 IL1B IKBKB FAS CXCL8
10
Akt Signaling 63
Show member pathways
 13.49 PDGFRA MTOR IL6 IL1B IKBKB FAS
11
PAK Pathway 63
Show member pathways
 13.41 PDGFRA IL6 IL1B IKBKB FAS ELK1
12
IL-2 Pathway 63
Show member pathways
 13.33 MTOR IL1B IKBKB ELK1 EGFR CREB1
13
Toll-like Receptor Signaling Pathway 36 1
Show member pathways
 13.31 IRF3 IL6 IL1B IKBKB FAS ELK1
14
Cytokine Signaling in Immune system 65
Show member pathways
 13.31 PDGFRA IRF3 IL6 IL1B IKBKB HLA-G
15
TNFR1 Pathway 63
Show member pathways
 13.22 MTOR IL6 IKBKB FAS ELK1 EGFR
16
p70S6K Signaling 63
Show member pathways
 13.19 PDGFRA MTOR IL6 IKBKB ELK1 EGFR
17
Actin Nucleation by ARP-WASP Complex 63
Show member pathways
 13.08 PDGFRA HLA-G HLA-E HLA-C HLA-A EGFR
18
CCR5 Pathway in Macrophages 63
Show member pathways
 13.04 IKBKB FAS ELK1 CXCL8 CHUK CCR1
19
NFAT and Cardiac Hypertrophy 63
Show member pathways
 13.03 PDGFRA MTOR IL6 IKBKB ELK1 EGFR
20
Endometrial cancer 36
Show member pathways
 13.02 PDGFRA MTOR IKBKB ELK1 EGFR CREB1
21
Pathways in cancer 36
12.94 PDGFRA MTOR IL6 IKBKB FAS ELK1
22
Common Cytokine Receptor Gamma-Chain Family Signaling Pathways 64
Show member pathways
 12.92 MTOR IL6 IKBKB ELK1 CREB1 CHUK
23
MAPK signaling pathway 36 1
12.92 PDGFRA IL1B IKBKB FAS ELK1 EGFR
24
Allograft rejection 1 36
Show member pathways
 12.92 PDGFRA IL6 IL1B HLA-G HLA-E HLA-C
25
Salmonella infection (KEGG) 36
Show member pathways
 12.9 IL6 IL1B IKBKB FAS CXCL8 CHUK
26
Toll-Like receptor Signaling Pathways 64
Show member pathways
 12.88 IRF3 IL6 IL1B IKBKB EGFR CXCL8
27
Downstream signaling events of B Cell Receptor (BCR) 65
Show member pathways
 12.87 PDGFRA MTOR IKBKB EGFR CREB1 CHUK
28
Development HGF signaling pathway 23
Show member pathways
 12.86 MTOR IKBKB FAS ELK1 CREB1 CASP3
29
Apoptosis Modulation and Signaling 1
Show member pathways
 12.85 IRF3 IKBKB FAS CHUK CDKN2A CASP3
30
Ras signaling pathway 36
Show member pathways
 12.84 PDGFRA IKBKB ELK1 EGFR CHUK
31
NF-KappaB Family Pathway 63
Show member pathways
 12.82 IL6 IL1B IKBKB EGFR CHUK
32
4-1BB Pathway 63
Show member pathways
 12.82 PDGFRA IL1B IKBKB FAS EGFR CREB1
33
Measles 36
Show member pathways
 12.78 IRF3 IL6 IL1B IKBKB HLA-G HLA-E
34
Immune response IL-23 signaling pathway 23
Show member pathways
 12.76 PDGFRA IL6 IL1B IKBKB ELK1 EGFR
35
TRAF Pathway 63
Show member pathways
 12.75 IL1B IKBKB FAS ELK1 CHUK CASP3
36
T cell receptor signaling pathway 36
Show member pathways
 12.75 MTOR IL6 IL1B IKBKB FAS EGFR
37
ErbB signaling pathway 36 1
Show member pathways
 12.74 PDGFRA MTOR IL6 ELK1 EGFR
38
NF-kappaB Signaling 4
12.73 IRF3 IL1B IKBKB FAS CHUK CCL5
39
Th17 cell differentiation 36
Show member pathways
 12.72 MTOR IL6 IL1B IKBKB CHUK
40
Cytosolic sensors of pathogen-associated DNA 65
Show member pathways
 12.71 IRF3 IL6 IL1B IKBKB CHUK CCL5
41
MicroRNAs in cancer 36
12.69 PDGFRA MTOR IKBKB EGFR CDKN2A CASP3
42
Interferon gamma signaling 65
Show member pathways
 12.67 IRF3 HLA-G HLA-E HLA-C HLA-A
43
Immune response Role of DAP12 receptors in NK cells 23
Show member pathways
 12.67 HLA-G HLA-E HLA-C HLA-A FAS CASP3
44
Herpes simplex virus 1 infection 36
12.67 MTOR IRF3 IL6 IL1B IKBKB HLA-G
45
Prolactin Signaling Pathway 1 36
Show member pathways
 12.65 MTOR IL1B IKBKB ELK1 CREB1 CHUK
46
mTOR signaling pathway (KEGG) 36
Show member pathways
 12.64 PDGFRA MTOR IKBKB EGFR CHUK
47
VEGF Signaling 66
Show member pathways
 12.64 MTOR IKBKB ELK1 EGFR CASP3
48
Insulin receptor recycling 65
Show member pathways
 12.64 IKBKB EGFR CXCL8 CHUK CCL5 CASP3
49
Antigen processing-Cross presentation 65
Show member pathways
 12.64 IKBKB HLA-G HLA-E HLA-C HLA-A CHUK
50
PI3K-Akt signaling pathway 36
Show member pathways
 12.64 PDGFRA MTOR IRF3 IL6 IKBKB HLA-G
Sources

GO Terms for Human Cytomegalovirus Infection

About this section

Cellular components related to Human Cytomegalovirus Infection according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 Golgi membrane GO:0000139 9.91 MTOR HLA-G HLA-E HLA-C HLA-A EGFR
2 cell surface GO:0009986 9.88 PDGFRA HLA-E HLA-C HLA-A FAS EGFR
3 external side of plasma membrane GO:0009897 9.85 PDGFRA HLA-G HLA-E FAS CCR1
4 recycling endosome membrane GO:0055038 9.67 HLA-G HLA-E HLA-C HLA-A
5 early endosome membrane GO:0031901 9.65 HLA-G HLA-E HLA-C HLA-A EGFR
6 phagocytic vesicle membrane GO:0030670 9.62 HLA-G HLA-E HLA-C HLA-A
7 CD40 receptor complex GO:0035631 9.51 IKBKB CHUK
8 IkappaB kinase complex GO:0008385 9.49 IKBKB CHUK
9 death-inducing signaling complex GO:0031264 9.48 FAS CASP3
10 ER to Golgi transport vesicle membrane GO:0012507 9.46 HLA-G HLA-E HLA-C HLA-A
11 integral component of lumenal side of endoplasmic reticulum membrane GO:0071556 9.26 HLA-G HLA-E HLA-C HLA-A
12 MHC class I protein complex GO:0042612 8.92 HLA-G HLA-E HLA-C HLA-A

Biological processes related to Human Cytomegalovirus Infection according to GeneCards Suite gene sharing:

(show top 50) (show all 52)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 10.17 IRF3 IL6 IKBKB ELK1 EGFR CREB1
2 phosphorylation GO:0016310 10.16 PDGFRA MTOR IKBKB EGFR CHUK CDKN2A
3 innate immune response GO:0045087 10.12 IRF3 IKBKB HLA-E HLA-C HLA-A CHUK
4 positive regulation of gene expression GO:0010628 10.11 MTOR IL6 IL1B CXCL8 CDKN2A
5 protein phosphorylation GO:0006468 10.08 PDGFRA MTOR IKBKB EGFR CREB1 CHUK
6 positive regulation of apoptotic process GO:0043065 10.07 IL6 FAS CREB1 CDKN2A CASP3
7 viral process GO:0016032 10.03 PDGFRA IRF3 IKBKB HLA-E HLA-C HLA-A
8 inflammatory response GO:0006954 10.02 IL6 IL1B IKBKB CXCL8 CHUK CCR1
9 positive regulation of ERK1 and ERK2 cascade GO:0070374 10 PDGFRA EGFR CCR1 CCL5
10 regulation of immune response GO:0050776 10 HLA-G HLA-E HLA-C HLA-A
11 positive regulation of protein phosphorylation GO:0001934 9.99 MTOR IL1B FAS EGFR
12 positive regulation of cell migration GO:0030335 9.99 PDGFRA IL1B EGFR CCR1 CCL5
13 cytokine-mediated signaling pathway GO:0019221 9.99 IL6 IL1B CXCL8 CCR1 CCL5 CASP3
14 response to lipopolysaccharide GO:0032496 9.98 IRF3 IL1B CHUK CASP3
15 cellular response to lipopolysaccharide GO:0071222 9.97 IRF3 IL6 IL1B CXCL8
16 positive regulation of transcription, DNA-templated GO:0045893 9.97 IRF3 IL6 IL1B IKBKB ELK1 EGFR
17 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.96 IL6 IL1B IKBKB CHUK
18 chemotaxis GO:0006935 9.96 PDGFRA CXCL8 CCR1 CCL5
19 cellular response to tumor necrosis factor GO:0071356 9.92 IKBKB CXCL8 CHUK CCL5
20 cellular response to mechanical stimulus GO:0071260 9.89 IL1B FAS EGFR
21 regulation of insulin secretion GO:0050796 9.88 IL6 IL1B CCL5
22 chemokine-mediated signaling pathway GO:0070098 9.88 CXCL8 CCR1 CCL5
23 cellular response to organic cyclic compound GO:0071407 9.88 IL1B CCL5 CASP3
24 wound healing GO:0042060 9.88 PDGFRA MTOR EGFR CASP3
25 positive regulation of T cell proliferation GO:0042102 9.87 IL6 IL1B CCL5
26 response to activity GO:0014823 9.85 MTOR IL6 CREB1
27 positive regulation of epithelial to mesenchymal transition GO:0010718 9.83 MTOR IL6 IL1B
28 antigen processing and presentation GO:0019882 9.83 HLA-E HLA-C HLA-A
29 positive regulation of smooth muscle cell proliferation GO:0048661 9.83 MTOR IL6 EGFR CCL5
30 cellular response to virus GO:0098586 9.82 IRF3 IL6 CHUK
31 cellular response to reactive oxygen species GO:0034614 9.8 PDGFRA EGFR CHUK
32 interferon-gamma-mediated signaling pathway GO:0060333 9.8 IRF3 HLA-G HLA-E HLA-C HLA-A
33 response to amino acid GO:0043200 9.79 MTOR CHUK CASP3
34 lipopolysaccharide-mediated signaling pathway GO:0031663 9.78 IRF3 IL1B CCL5
35 TRIF-dependent toll-like receptor signaling pathway GO:0035666 9.77 IRF3 IKBKB CHUK
36 type I interferon signaling pathway GO:0060337 9.77 IRF3 HLA-G HLA-E HLA-C HLA-A
37 antigen processing and presentation of peptide antigen via MHC class I GO:0002474 9.76 HLA-G HLA-E HLA-C HLA-A
38 positive regulation of T cell mediated cytotoxicity GO:0001916 9.73 HLA-G HLA-E HLA-A
39 positive regulation of glial cell proliferation GO:0060252 9.72 MTOR IL6 IL1B
40 regulation of establishment of endothelial barrier GO:1903140 9.71 IL1B IKBKB
41 positive regulation of natural killer cell cytokine production GO:0002729 9.69 HLA-G HLA-E
42 vascular endothelial growth factor production GO:0010573 9.68 IL6 IL1B
43 antigen processing and presentation of endogenous peptide antigen via MHC class Ib GO:0002476 9.67 HLA-G HLA-E
44 protection from natural killer cell mediated cytotoxicity GO:0042270 9.67 HLA-G HLA-E HLA-A
45 positive regulation of CD8-positive, alpha-beta T cell proliferation GO:2000566 9.64 HLA-E HLA-A
46 CD8-positive, alpha-beta T cell activation GO:0036037 9.63 HLA-E HLA-A
47 positive regulation of cellular biosynthetic process GO:0031328 9.62 CXCL8 CCL5
48 positive regulation of CD8-positive, alpha-beta T cell activation GO:2001187 9.58 HLA-E HLA-A
49 antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-independent GO:0002480 9.56 HLA-G HLA-E HLA-C HLA-A
50 antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independent GO:0002486 9.46 HLA-G HLA-E HLA-C HLA-A

Molecular functions related to Human Cytomegalovirus Infection according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.16 PDGFRA MTOR IRF3 IL6 IL1B IKBKB
2 identical protein binding GO:0042802 10.08 MTOR IRF3 IKBKB HLA-G FAS EGFR
3 kinase activity GO:0016301 9.91 PDGFRA MTOR IKBKB EGFR CHUK CDKN2A
4 protein homodimerization activity GO:0042803 9.88 PDGFRA IRF3 IKBKB HLA-G CHUK CCL5
5 protein-containing complex binding GO:0044877 9.85 PDGFRA MTOR EGFR CHUK CASP3
6 cytokine activity GO:0005125 9.81 IL6 IL1B CXCL8 CCL5
7 transferrin receptor binding GO:1990459 9.54 IKBKB CHUK
8 T cell receptor binding GO:0042608 9.52 HLA-E HLA-A
9 beta-2-microglobulin binding GO:0030881 9.49 HLA-E HLA-A
10 protein kinase activity GO:0004672 9.43 PDGFRA MTOR IKBKB EGFR CHUK CCL5
11 CD8 receptor binding GO:0042610 9.37 HLA-G HLA-A
12 TAP binding GO:0046977 9.32 HLA-C HLA-A
13 IkappaB kinase activity GO:0008384 9.26 IKBKB CHUK
14 peptide antigen binding GO:0042605 8.92 HLA-G HLA-E HLA-C HLA-A
Sources

Sources for Human Cytomegalovirus Infection

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....